SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$224M
Q3 2023
Positions
31
Filings on Record
31
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Lion Point Capital, LP reported $224M in U.S.-listed holdings across 31 positions for Q3 2023.

The portfolio is heavily concentrated: SMTC alone accounts for 28.1% of reported value.

Compared with Q2 2023, the fund opened 8 new positions and exited 7.

Portfolio Metrics

Turnover
+14.8%
vs prior filed quarter
Top-10 Concentration
+44.3%
share of reported value
Largest Position
+28.1%
Semtech
New / Exited
8 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 75.0%ETP: 22.5%Other: 2.2%US DOMESTIC: 0.3%
  • Common Stock · 75.0% · $168M
  • ETP · 22.5% · $51M
  • Other · 2.2% · $5M
  • US DOMESTIC · 0.3% · $647,930

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ISHARES TRNEW+165.0K165.0K+$29M$29M
AVADEL PHARMACEUTICALS PLCNEW+80.0K80.0K+$824,000$824,000
TVTXTRAVERE THERAPEUTICS INCNEW+78.0K78.0K+$697,320$697,320
HUMAHUMACYTE INCNEW+235.0K235.0K+$688,550$688,550
TRAVERE THERAPEUTICS INCNEW+1.00M1.00M+$647,930$647,930
REPLREPLIMUNE GROUP INCNEW+35.0K35.0K+$598,850$598,850
HARPUSDHARPOON THERAPEUTICS INCNEW+82.5K82.5K+$332,306$332,306
CHVCHEVRON CORP NEWNEW+4646+$7,757$7,757

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SMTCSEMTECH CORPhistory →COM28.14%$63M2.45M
2MARINUS PHARMACEUTICALS INCCOM NEW7.70%$17M2.15M
3ARDXARDELYX INChistory →COM2.14%$5M1.18M
40LSBURGERFI INTERNATIONAL INChistory →COM1.42%$3M2.75M
5BATLBATTALION OIL CORPORATIONhistory →COM1.05%$2M380.9K
6KINIKSA PHARMACEUTICALS LTDCOM CL A1.01%$2M130.7K
7IM8NINSMED INCCOM PAR $.010.79%$2M70.3K
8MCRB1EURSERES THERAPEUTICS INCCOM0.73%$2M691.8K
9BLUEBIRD BIO INCCOM0.72%$2M531.3K
10MISTMILESTONE PHARMACEUTICALS INCOM0.62%$1M450.2K
11TVTXTRAVERE THERAPEUTICS INCCOM · NOTE 2.250% 3/00.60%$1M1.08M
12CYMABAY THERAPEUTICS INCCOM0.55%$1M82.4K
13DC8ADURECT CORPCOM NEW0.47%$1M427.5K
14MIRMMIRUM PHARMACEUTICALS INCCOM0.38%$853,20027.0K
15FRXFENNEC PHARMACEUTICALS INCCOM0.37%$826,100110.0K
16AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.37%$824,00080.0K
17ACRSACLARIS THERAPEUTICS INCCOM0.35%$793,901115.9K
18HUMAHUMACYTE INCCOM0.31%$688,550235.0K
19REPLREPLIMUNE GROUP INCCOM0.27%$598,85035.0K
20SNDXSYNDAX PHARMACEUTICALS INCCOM0.22%$500,94034.5K
21WHWKAADI BIOSCIENCE INCCOM0.18%$398,92782.4K
22HARPUSDHARPOON THERAPEUTICS INCCOM NEW0.15%$332,30682.5K
23LUMOS PHARMA INCCOM0.13%$299,62090.8K
24MSFTMICROSOFT CORPCOM0.01%$31,575100
25GOOGALPHABET INCCAP STK CL C0.01%$13,185100
26CHVCHEVRON CORP NEWCOM0.00%$7,75746

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.